Despite these challenges, our review offers a more unified perspective on SMARCA4-altered malignancies, underscoring the importance of prospective studies, molecular stratification, and standardized reporting to enhance the understanding of treatment responses and prognoses in this rare tumor subset. The gene discussed is SMARCA4; the disease is neoplasm.